Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.60 |
| ▸ | RARB | P10826 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946501 | 1.00 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL9578575 | 1.00 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL7548158 | 1.00 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL14125959 | 1.00 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL10662876 | 0.98 | MAPT (0.71) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL1461142 | 0.94 | MAPT (0.73) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL10657063 | 0.89 | MAPT (0.75) | MAPTTP53TSHRL3MBTL1HCAR3 | |
| SCHEMBL7555804 | 0.86 | MAPT (0.50) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL6953681 | 0.86 | NNMT (0.59) | MAPTTP53TSHRPLA2G4B | |
| SCHEMBL7219864 | 0.85 | LMNA (0.62) | MAPTTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123639-B1 | PROCESS FOR PRODUCTION OF 2,3'-BIPYRIDYL-6'-ONE | FUJIFILM FINECHEMICALS CO LTD (JP) | 2014-03-26 | — | — | EP | disclosed |
| EP-2123639-A1 | PROCESS FOR PRODUCTION OF 2,3'-BIPYRIDYL-6'-ONE | Fujifilm Finechemicals Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | MAPT 4755/4885TP53 4875/4885TSHR 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.